jnj-56136379
Small moleculeexperimental
Clinical trial activity
14 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Dec 17, 2015 (NCT02662712)
Timeline
Indications
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- jnj-56136379
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04853524 | Phase 1 | May 6, 2021 | Janssen Pharmaceutica NV |
| NCT04585789 | Phase 2 | Jan 15, 2021 | Janssen Pharmaceutica NV |
| NCT04439539 | Phase 2 | Sep 14, 2020 | Janssen Pharmaceutica NV |
| NCT04474210 | Phase 1 | Aug 19, 2020 | Janssen Pharmaceutica NV |
| NCT04208399 | Phase 1 | Jan 15, 2020 | Janssen Pharmaceutica NV |
| NCT04288310 | Phase 2 | Nov 6, 2019 | Janssen Pharmaceutica NV |
| NCT04129554 | Phase 2 | Nov 4, 2019 | Janssen Pharmaceutica NV |
| NCT03982186 | Phase 2 | Jul 17, 2019 | Janssen Pharmaceutica NV |
| NCT03945539 | Phase 1 | May 15, 2019 | Janssen Pharmaceutica NV |
| NCT03864601 | Phase 1 | Apr 9, 2019 | Janssen Pharmaceutica NV |
| NCT03361956 | Phase 2 | Feb 13, 2018 | Janssen Pharmaceutica NV |
| NCT03111511 | Phase 1 | Mar 27, 2017 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02933580 | Phase 1 | Oct 12, 2016 | Johnson and Johnson |
| NCT02662712 | Phase 1 | Dec 17, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 13 | 11 | 2 | 2015 |
| Johnson and Johnson | For profit | 3 | 3 | 1 | 2015 |
2 organizations
Page 1 / 1